key: cord-1013011-eihz11y0
authors: Camporota, Luigi; Gattinoni, Luciano; Marini, John J.
title: “Established” Respiratory Treatment in Acute Respiratory Distress Syndrome: Scientific Rigor or a Square Peg in a Round Hole?
date: 2021-03-15
journal: Am J Respir Crit Care Med
DOI: 10.1164/rccm.202011-4163le
sha: ae87acbfbe1e4143958704fca53094edb2df7d7d
doc_id: 1013011
cord_uid: eihz11y0

nan

Reply to Camporota et al.

Acute respiratory distress syndrome (ARDS) is a heterogeneous syndrome. Given this heterogeneity, there have been many efforts to define subgroups of patients with ARDS: by etiology, by respiratory mechanics, by the distribution of radiographic abnormalities, by the severity of gas exchange abnormality, or by biomarkers. In their response to the editorial "Novel Phenotypes in Respiratory Failure: Same as It Ever Was" (1), Dr. Camporota, Dr. Gattinoni, and Dr. Marini articulate the plausible and widely held hypothesis that such subgroups would benefit from distinct treatment strategies. Indeed, this hypothesis has animated much of the recent research literature on ARDS. To date, however, it has proven surprisingly difficult to prospectively demonstrate a mortality benefit from any particular tailored approach. Prone ventilation has proven 

Novel phenotypes in respiratory failure: same as it ever was

Low tidal volume versus non-volume-limited strategies for patients with acute respiratory distress syndrome: a systematic review and metaanalysis

Compliance phenotypes in early acute respiratory distress syndrome before the COVID-19 pandemic

Tidal volume reduction in patients with acute lung injury when plateau pressures are not high

Dealing with the CARDS of COVID-19